What is the treatment approach for a patient with pulmonary fibrosis, considering their overall health status and medical history?

Treatment of Pulmonary Fibrosis

For patients with idiopathic pulmonary fibrosis (IPF), initiate antifibrotic therapy with either pirfenidone or nintedanib immediately upon diagnosis, as these medications slow disease progression and reduce FVC decline, though they do not halt progression or improve quality of life. 1, 2

Pharmacological Treatment

First-Line Antifibrotic Therapy

Both pirfenidone and nintedanib are FDA-approved first-line treatments for IPF and should be started at diagnosis. 1, 2

• Pirfenidone is indicated for IPF treatment, particularly in patients with FVC >50% predicted and DLCO >35% predicted 1, 2

  • Dosing: 2,403 mg/day divided into three doses taken with food 2
  • Mechanism: Anti-inflammatory, antioxidative, and antiproliferative effects 1
  • Efficacy: Reduces mean FVC decline by approximately 193 mL compared to placebo at 52 weeks 2
  • Common adverse effects: Nausea, rash, fatigue, diarrhea, photosensitivity, elevated liver enzymes 1
  • Management: Gradual dose titration, take with food, avoid sun exposure, monitor liver function monthly for first 6 months 1

• Nintedanib is recommended for IPF and progressive pulmonary fibrosis (PPF) 1

  • Mechanism: Blocks pathways involved in fibrogenesis 1
  • Common adverse effects: Diarrhea, nausea, abdominal pain, vomiting, elevated liver enzymes 1
  • Management: Dose reduction and temporary treatment interruption as needed 1

For Progressive Pulmonary Fibrosis (Non-IPF)

Nintedanib is the first-line therapy for progressive fibrotic interstitial lung diseases other than IPF after failure of standard management specific to the underlying ILD. 1

Treatments to AVOID

Do NOT use the following therapies as they increase mortality or lack efficacy: 1

• Triple therapy with prednisone, azathioprine, and N-acetylcysteine (increases mortality) 1
• Combined corticosteroids and immunosuppressants for stable IPF 3
• Oral anti-vitamin K anticoagulants for treating IPF 1
• Ambrisentan (contraindicated in IPF) 1
• Corticosteroids alone for stable disease (only for acute exacerbations or incapacitating cough) 1

Non-Pharmacological Management

Oxygen Supplementation

Prescribe supplemental oxygen for all patients with oxygen saturation <88% during 6-minute walk test or at rest. 3

• Measure oxygen saturation at rest and with exertion at every visit regardless of symptoms 3
• Long-term oxygen therapy is indicated for severe hypoxemia at rest 1

Pulmonary Rehabilitation

Refer patients for pulmonary rehabilitation to improve exercise capacity and quality of life. 3, 1

Lung Transplantation

Evaluate and list patients for lung transplantation at the time of diagnosis if they have increased risk of mortality. 3

• Consider transplantation for patients aged <65 years with severe or worsening disease 1
• Lung transplantation is the only intervention proven to improve survival 4

Monitoring Strategy

Monitor disease progression every 3-6 months with pulmonary function testing (FVC and DLCO) and 6-minute walk test. 3

Disease Progression Criteria

Progressive disease is defined by at least two of the following within one year: 3

1. Worsening respiratory symptoms (dyspnea, cough) 3
2. Physiological decline:
   • Absolute FVC decline >5% predicted, OR 3
   • Absolute DLCO decline >10% predicted 3
3. Radiological progression on HRCT: 3
   • Increased traction bronchiectasis/bronchiolectasis 3
   • New ground-glass opacity with traction bronchiectasis 3
   • New or increased honeycombing 3
   • Increased extent of reticular abnormality 3

Monitoring Schedule

• Pulmonary function tests: Every 3-6 months or sooner if clinically indicated 3
• Oxygen saturation: At rest and with exertion at every visit 3
• HRCT: Annually if clinical suspicion of worsening or risk of lung cancer 3
• Liver function tests: Monthly for first 6 months on pirfenidone, then every 3 months 1

Management of Complications

Acute Exacerbations

Treat acute exacerbations with corticosteroids (weak recommendation). 3

• Obtain HRCT if concern for acute exacerbation 3
• Do NOT use mechanical ventilation for the majority of patients with respiratory failure due to IPF progression (associated with poor outcomes) 3

Comorbidities to Screen and Treat

Monitor and treat the following comorbidities: 3, 4

• Pulmonary hypertension 3, 4
• Gastroesophageal reflux 3, 4
• Obstructive sleep apnea 3, 4
• Lung cancer (10-15% increased risk) 3, 4
• Pulmonary embolism 3
• Coronary artery disease 3

Palliative Care and Symptom Management

Involve palliative care early to manage symptoms (cough, dyspnea, anxiety) and improve quality of life. 3

• Focus on symptom control rather than disease modification 3
• Discuss advanced directives in the ambulatory setting 3
• Address patient values and preferences regarding treatment goals 3

Preventive Measures

Administer annual influenza and pneumococcal vaccinations to all IPF patients. 1

Clinical Trial Enrollment

Inform all patients about available clinical trials at all disease stages. 3

Common Pitfalls to Avoid

• Do not delay antifibrotic therapy initiation—start at diagnosis 1, 4
• Do not use FVC or DLCO changes <5% and <10% respectively as sole indicators of progression (overlap with test variability) 3
• Do not routinely screen for complications without clinical indication (no evidence for routine annual HRCT for lung cancer surveillance) 3
• Do not continue pharmacological therapy if patients experience intolerable adverse effects without attempting dose modification first 1
• Do not use corticosteroids as monotherapy for stable IPF (only for acute exacerbations) 3, 1